Company Filing History:
2 out of 1,210 
2 out of 517 
2 out of 2,968 
Years Active: 2022-2025
Title: Nikolaos Patsoukis: Innovator in Cancer Research
Introduction
Nikolaos Patsoukis is a prominent inventor based in Boston, MA, known for his significant contributions to cancer research. He holds two patents that focus on innovative methods for modulating programmed death 1 (PD-1) signaling, which is crucial in the field of immunotherapy.
Latest Patents
His latest patents include a method of assessing the efficacy of a test agent for modulating PD-1 signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies. This invention is based on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1. It also encompasses immunoglobulins, polypeptides, and nucleic acids, along with methods for using these antibodies for diagnostic, prognostic, and therapeutic purposes. Another patent focuses on anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, detailing methods of making and using these antibodies for similar applications.
Career Highlights
Patsoukis has worked with esteemed institutions such as Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. His work has significantly advanced the understanding of PD-1 signaling and its implications in cancer treatment.
Collaborations
He has collaborated with notable colleagues, including Gordon James Freeman and Vassiliki A. Boussiotis, contributing to a rich environment of research and innovation.
Conclusion
Nikolaos Patsoukis continues to be a vital figure in cancer research, with his patents paving the way for new therapeutic strategies. His work exemplifies the intersection of innovation and healthcare, aiming to improve patient outcomes in cancer treatment.